-
Cancer company Epizyme Inc. (Cambridge, Mass.) amended its IPO and said it plans to sell 4.3 million shares at $13-$15. At the $14 mid-point, Epizyme would raise $60 million and be valued at $375 million. Earlier this …
Published on 5/21/2013
-
The French government's Fonds National d'Amorcage and the not-for-profit AFM-Telethon launched a seed fund to invest in biotherapeutics for rare diseases. The new fund, which will be managed by CDC Enterprises launched …
Published on 5/21/2013
-
Merck & Co. Inc. (NYSE:MRK) said it will repurchase about $5 billion in stock, or about 99.5 million shares, from Goldman Sachs under an accelerated share repurchase program. The program is slated to be completed by Nov…
Published on 5/21/2013
-
Athyrium Capital Management and partner Neuberger Berman closed a life sciences private credit fund, Athyrium Opportunities Fund L.P., at $507 million, well above the original target of $350 million. The fund, which the…
Published on 5/20/2013
-
Effector Therapeutics Inc. (San Diego, Calif.) raised $45 million in a tranched series A round co-led by U.S. Venture Partners; Abingworth; Novartis Venture Funds; and SR One. Astellas Venture Management; Osage …
Published on 5/20/2013
-
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and NPS Pharmaceuticals Inc. (NASDAQ:NPSP) both announced plans late Monday to raise money in follow-ons. Ironwood proposed to sell 10.5 million shares in a follow-on …
Published on 5/20/2013
-
Cancer company Karyopharm Therapeutics Inc. (Natick, Mass.) raised $48.2 million in a series B round led by an undisclosed private investor. New investor Delphi Ventures and additional undisclosed investors participated…
Published on 5/20/2013
-
Diagnostics company NanoString Technologies Inc. (Seattle, Wash.) filed to raise up to $86.3 million in an IPO underwritten by JPMorgan; Morgan Stanley; Leerink; and Baird. Earlier this year, NanoString launched its …
Published on 5/20/2013
-
Kamada Ltd. (Tel Aviv:KMDA) said it now plans to raise about $60 million through the sale and listing of 5.6 million shares on NASDAQ in a follow-on. The company also added RBC Capital Markets; Oppenheimer; and Chardan …
Published on 5/17/2013
-
Ambit Biosciences Corp. (NASDAQ:AMBI) was off $0.61 to $7.39 in its first day of trading on Thursday after the company raised $65 million through the sale of 8.1 million shares at $8 in an IPO. Citigroup; Leerink; BMO …
Published on 5/16/2013
-
Cancer companies Stemline Therapeutics Inc. (NASDAQ:STML) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised a combined $80 million in follow-ons on Thursday. Stemline raised $60 million in a bumped-up offering …
Published on 5/16/2013
-
Merck KGaA (Xetra:MRK) expanded to EUR 100 million ($129.7 million) its MS Ventures fund. The strategic fund was formed in 2009 with EUR 40 million ($51.9 million) to invest in biotech startups working in areas …
Published on 5/16/2013
-
PTC Therapeutics Inc. (South Plainfield, N.J.) filed to raise up to $85 million in an IPO underwritten by JPMorgan; Credit Suisse; Cowen; and Wedbush. PTC, which raised $60 million in a venture round in March, pulled …
Published on 5/16/2013
-
Vivus Inc. (NASDAQ:VVUS) raised $220 million through the sale of 4.5% unsecured senior convertible notes due May 1, 2020. The notes initially convert at $14.86, which is a 9% premium to Vivus' close of $13.59 on Tuesday…
Published on 5/16/2013
-
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) raised $100 million through the sale of 8 million shares at $12.50 in a follow-on underwritten by Jefferies; Cowen; JMP Securities; Needham; Ladenburg Thalmann; Roth Capital …
Published on 5/15/2013
-
Ambit Biosciences Corp. (San Diego, Calif.) amended its IPO and now plans to sell more shares at a lower price. The company plans to sell 8.1 million shares at $8, which would raise $65 million and value the company at…
Published on 5/15/2013
-
Gene therapy company bluebird bio Inc. (Cambridge, Mass.) filed to raise up to $86.3 million in an IPO underwritten by JPMorgan; BofA Merrill Lynch; Cowen; Canaccord; and Wedbush. Late this year, the biotech plans to …
Published on 5/15/2013
-
Cancer immunotherapy company Kite Pharma Inc. (Los Angeles, Calif.) raised $20 million in a series A round. The company also converted $15 million in outstanding promissory notes from Kite's seed round into series A …
Published on 5/15/2013
-
Rockwell Medical Technologies Inc. (NASDAQ:RMTI) raised $35 million through the sale of 11.5 million shares at $3.05 in a follow-on underwritten by Chardan Capital Markets; Summer Street; and C&Co/Prince Ridge. Rockwell…
Published on 5/15/2013
-
Tokai Pharmaceuticals Inc. (Cambridge, Mass.) raised $35.5 million in a series E round from existing investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors. Tokai's galeterone …
Published on 5/15/2013
-
Vivus Inc. (NASDAQ:VVUS) said it plans to raise $200 million through the sale of unsecured senior convertible notes due May 1, 2020. The company markets obesity drug Qsymia phentermine/topiramate in the U.S. Last week, …
Published on 5/15/2013
-
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) proposed a follow-on late Tuesday underwritten by Jefferies; Cowen; JMP Securities; and Needham. Acadia plans to submit an NDA to FDA for pimavanserin around the end of next …
Published on 5/14/2013
-
Callidus Biopharma Inc. (Doylestown, Pa.) debuted on Tuesday with $4.6 million in a series A round led by two undisclosed investors, with participation from undisclosed private investors. Callidus is attaching insulin-…
Published on 5/14/2013
-
Esperion Therapeutics Inc. (Plymouth, Mich.) filed to raise up to $70 million in an IPO underwritten by Credit Suisse; Citigroup; JMP Securities; and Nicolaus Weisel. Esperion's ETC-1002 is in two Phase IIa trials to …
Published on 5/14/2013
-
Healthcare VC firm Third Rock Ventures named John Maraganore, CEO of RNAi company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), a venture partner. Third Rock also named Daniel Lynch and Steven Paul as venture partners. …
Published on 5/14/2013